Trial Profile

Phase II study of necitumumab and pembrolizumab in patients with PD-L1 high-expressing non-small-cell lung cancer (K-TAIL-202)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 11 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Necitumumab (Primary) ; Pembrolizumab (Primary)
Indications Adenocarcinoma; Carcinoma; Non-small cell lung cancer; Squamous cell cancer
Focus Therapeutic Use
Acronyms K-TAIL-202

Most Recent Events

05 Jun 2024 New trial record
10 Apr 2024 Primary endpoint (objective response rate (ORR)) has been met as per results presented at the 115th Annual Meeting of the American Association for Cancer Research.
10 Apr 2024 Results evaluating the effectiveness of the novel combination of pembrolizumab and necitumumab as first-line therapy in patients having advanced NSCLC with PD-L1 expression of 50% or higher presented at the 115th Annual Meeting of the American Association for Cancer Research.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com